ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer
Phase 3 data for Merck’s Kelun-Biotech-partnered TROP2-directed antibody-drug conjugate have boosted analyst expectations for a key pillar of the company’s post-Keytruda strategy. Merck has ceded a head start in the TROP2 space, with Gilead Sciences …